In the preceding three months, 7 analysts have released ratings for Charles River CRL, presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 4 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 3 | 1 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $273.29, a high estimate of $290.00, and a low estimate of $250.00. Witnessing a positive shift, the current average has risen by 6.93% from the previous average price target of $255.57.
Interpreting Analyst Ratings: A Closer Look
The standing of Charles River among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Eric Coldwell | Baird | Lowers | Outperform | $270.00 | $282.00 |
| David Toung | Argus Research | Raises | Buy | $290.00 | $240.00 |
| Ross Muken | Evercore ISI Group | Raises | Outperform | $265.00 | $260.00 |
| Dan Brennan | UBS | Raises | Buy | $290.00 | $270.00 |
| Patrick Donnelly | Citigroup | Raises | Neutral | $250.00 | $215.00 |
| Eric Coldwell | Baird | Raises | Outperform | $268.00 | $252.00 |
| Tycho Peterson | JP Morgan | Raises | Overweight | $280.00 | $270.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Charles River. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Charles River compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Charles River's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into Charles River's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Charles River analyst ratings.
Get to Know Charles River Better
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Key Indicators: Charles River's Financial Health
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining Charles River's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -7.85% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Charles River's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 18.46%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Charles River's ROE stands out, surpassing industry averages. With an impressive ROE of 5.42%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Charles River's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.37%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.85, caution is advised due to increased financial risk.
Understanding the Relevance of Analyst Ratings
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
